| Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma SM Castellino, Q Pei, SK Parsons, D Hodgson, K McCarten, T Horton, ... New England Journal of Medicine 387 (18), 1649-1660, 2022 | 53 | 2022 |
| Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group L Giulino-Roth, Q Pei, A Buxton, R Bush, Y Wu, SL Wolden, LS Constine, ... Blood 137 (11), 1449-1456, 2021 | 22 | 2021 |
| Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials JM Kahn, Q Pei, DL Friedman, J Kaplan, FG Keller, D Hodgson, Y Wu, ... The Lancet Haematology 9 (1), e49-e57, 2022 | 13 | 2022 |
| Continuous albuterol with benzalkonium in children hospitalized with severe asthma MC Pertzborn, S Prabhakaran, M Abu-Hasan, D Baker, S Wu, Y Wu, ... Pediatrics 145 (4), 2020 | 9 | 2020 |
| Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group … SM Castellino, Q Pei, SK Parsons, DC Hodgson, K McCarten, A Punnett, ... Journal of Clinical Oncology 40 (16_suppl), 7504-7504, 2022 | 6 | 2022 |
| Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study SA Milgrom, J Kim, Q Pei, I Lee, BS Hoppe, Y Wu, D Hodgson, S Kessel, ... British Journal of Haematology 201 (6), 1192-1199, 2023 | 4 | 2023 |
| Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis A Parekh, FG Keller, KM McCarten, S Kessel, S Cho, Q Pei, Y Wu, ... Blood, The Journal of the American Society of Hematology 140 (10), 1086-1093, 2022 | 4 | 2022 |
| Importance of central imaging review in a pediatric Hodgkin lymphoma trial using positron emission tomography response adapted radiation therapy BS Hoppe, KM McCarten, Q Pei, S Kessel, A Alazraki, JC Mhlanga, ... International Journal of Radiation Oncology* Biology* Physics 116 (5), 1025-1030, 2023 | 3 | 2023 |
| Patterns of initial relapse from a phase 3 study of response-based therapy for high-risk Hodgkin lymphoma (AHOD0831): a report from the Children's oncology group RR Parikh, KM Kelly, DC Hodgson, BS Hoppe, KM McCarten, K Karolczuk, ... International Journal of Radiation Oncology* Biology* Physics 112 (4), 890-900, 2022 | 3 | 2022 |
| Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma … H Dave, M Mai, A Datar, G Jenkins, Q Pei, Y Wu, FG Keller, SM Castellino, ... Blood 136, 41-42, 2020 | 3 | 2020 |
| Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group … SK Parsons, AM Rodday, Q Pei, FG Keller, Y Wu, TO Henderson, D Cella, ... Journal of patient-reported outcomes 7 (1), 113, 2023 | 1 | 2023 |
| Radiotherapy utilization and outcomes on a contemporary trial for pediatric high-risk Hodgkin lymphoma study BS Hoppe, S Castellino, Q Pei, AM Charpentier, F Keller, RM Vega, ... International Journal of Radiation Oncology, Biology, Physics 117 (2), S62-S63, 2023 | 1 | 2023 |
| Prognostic value of chest x‐ray‐and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831 AC Lo, I Lee, Q Pei, Y Wu, KM McCarten, BS Hoppe, DC Hodgson, ... Pediatric Blood & Cancer 70 (8), e30452, 2023 | 1 | 2023 |
| Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331 CL Schwartz, Q Pei, FG Keller, SY Cho, DC Hodgson, KM McCarten, ... Blood 140 (Supplement 1), 6565-6566, 2022 | 1 | 2022 |
| Peripheral neuropathy in children with high risk hodgkin lymphoma (HL): the role of protocol-stipulated dose modification in the children's oncology group (COG) AHOD1331 study SK Parsons, FG Keller, Q Pei, AM Rodday, J Belsky, Y Wu, A Punnett, ... Blood 140 (Supplement 1), 6550-6551, 2022 | 1 | 2022 |
| AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II … TO Henderson, B Hu, F Keller, Q Pei, Y Wu, B Hoppe, S Milgrom, S Yao, ... Blood 142, 3084, 2023 | | 2023 |
| Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma LJ Marks, K McCarten, Q Pei, Y Wu, KM Kelly, C Schwartz, S Wolden, ... Blood 142, 1699, 2023 | | 2023 |
| T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma SM Castellino, Q Pei, SK Parsons, D Hodgson, K Mccarten, T Horton, ... HemaSphere 6, 40, 2022 | | 2022 |
| P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL JE Flerlage, S Birz, SM Castellino, B Appel, B Furner, L Graglia, ... HemaSphere 6, 39-40, 2022 | | 2022 |
| PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study SA Milgrom, J Kim, BS Hoppe, Q Pei, Y Wu, AC Lo, S Kessel, ... International Journal of Radiation Oncology, Biology, Physics 111 (3), S79-S80, 2021 | | 2021 |
